AstraZeneca Unloads Four NDAs to ANI Pharmaceuticals in $46.5M Deal Post author:Sam Post published:December 28, 2017 Post category:BioPharma ANI Phamaceuticals funded the acquisitions through a combination of cash and debt. Source: BioSpace You Might Also Like AstraZeneca PLC Confirms CEO is Staying Put—For Now July 16, 2017 NicOx SA First Half 2017 Business And Financial Update September 7, 2017 Phoenix Molecular Designs Appoints Leading Oncology Expert As Chief Scientific Officer July 16, 2017
